Cambridge Investment Research Advisors
INFI

Cambridge Investment Research Advisors’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Cambridge Investment Research Advisors’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-22,245
Closed -$42K – 2319
2018
Q2 		$42K Buy
+22,245
New +$44.9K ﹤0.01% 2167

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Cambridge Investment Research Advisors's INFI Position: Q3 2018 in Review

Cambridge Investment Research Advisors sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2018, closing a stake of 22,245 shares — an estimated $42K sold.

Cambridge Investment Research Advisors first reported a position in INFI in Q2 2018 and held it in 1 quarter. The position peaked at $42K in Q2 2018. 63 funds tracked by Wall St. Rank hold INFI as of Q3 2018.

  • Cambridge Investment Research Advisors reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 22,245 Infinity Pharmaceuticals, Inc. shares in Q3 2018, an estimated $42K.
  • Cambridge Investment Research Advisors first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Infinity Pharmaceuticals, Inc. position peaked at $42K in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2018.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2018, filed 2 Nov 2018.